Modelling CHO clonal phenotype variance for optimal bioprocessing platform design

The project will use advanced screening, genome editing (e.g. CRISPR/Cas9)/synthetic biology and analytical technologies, to further develop an understanding of the cellular processes that limit and underpin cell metabolism, cell growth, recombinant protein product yield and quality. In turn, this understanding will be utilized to develop new CHO cell chassis and bioprocesses that enhance GSKs ability to rapidly generate cell lines making novel molecules at appropriate amounts and quality for investigation and progression towards clinical studies.